Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
haha, if the effect has been confirmed in human body, the clinical trails is not necessary to perform, is it?
effect in vitro, effect in animal, and then confirmed in human body, that is purpose of clinical trails
Marijuana is a good medicine for PSTD!
CBIS corporate with Echo Pharmaceuticals and Farmalyse in Amsterdam Biomed Cluster?
Echo Pharmaceuticals is a privately owned and rapidly growing specialized pharmaceutical company based in The Netherlands, founded in 2006. Our mission is to develop effective medicines, with a focus on cannabinoid-based compounds, and drug delivery technologies that contribute to better the quality of life for a wide range of patients. In 2009, we established our headquarters and clinical research center in Nijmegen, which is situated in an area of the Netherlands well-known for its ideal environment for businesses in life sciences and health.
Bactimm B.V. & Farmalyse B.V. offers contract services for the pharmaceutical, medical devices, cosmetics industry and hospitals, with dedicated centres of excellence for Microbiological and Pharma-Chemical Investigations.
Bactimm and Farmalyse are your partners for analytical services, laboratory investigations & international services that are customised to the requirements of the industry
Cannabis Science cure cancer
extract source
extract method
application on patients with different types of cancers
data analysis
improvement
product standard
....
cannabis cure cancer more
http://www.ncbi.nlm.nih.gov/pubmed/?term=cannabis+cancer
cannabis cure cancer 2
Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration.
Cannabidiol (CBD), a major non-psychotropic constituent of fiber-type cannabis plant, has been reported to possess diverse biological activities, including anti-proliferative effect on cancer cells. Although CBD is obtained from non-enzymatic decarboxylation of its parent molecule, cannabidiolic acid (CBDA), few studies have investigated whether CBDA itself is biologically active. Results of the current investigation revealed that CBDA inhibits migration of the highly invasive MDA-MB-231 human breast cancer cells, apparently through a mechanism involving inhibition of cAMP-dependent protein kinase A, coupled with an activation of the small GTPase, RhoA. It is established that activation of the RhoA signaling pathway leads to inhibition of the mobility of various cancer cells, including MDA-MB-231 cells. The data presented in this report suggest for the first time that as an active component in the cannabis plant, CBDA offers potential therapeutic modality in the abrogation of cancer cell migration, including aggressive breast cancers.
cannabis cure cancer 1
Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme.
Cannabinoids, the active components of marijuana and their derivatives, are currently investigated due to their potential therapeutic application for the management of many different diseases, including cancer. Specifically, ?(9)-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) - the two major ingredients of marijuana - have been shown to inhibit tumor growth in a number of animal models of cancer, including glioma. Although there are several pharmaceutical preparations that permit the oral administration of THC or its analogue nabilone or the oromucosal delivery of a THC- and CBD-enriched cannabis extract, the systemic administration of cannabinoids has several limitations in part derived from the high lipophilicity exhibited by these compounds. In this work we analyzed CBD- and THC-loaded poly-e-caprolactone microparticles as an alternative delivery system for long-term cannabinoid administration in a murine xenograft model of glioma. In vitro characterization of THC- and CBD-loaded microparticles showed that this method of microencapsulation facilitates a sustained release of the two cannabinoids for several days. Local administration of THC-, CBD- or a mixture (1:1 w:w) of THC- and CBD-loaded microparticles every 5 days to mice bearing glioma xenografts reduced tumour growth with the same efficacy than a daily local administration of the equivalent amount of those cannabinoids in solution. Moreover, treatment with cannabinoid-loaded microparticles enhanced apoptosis and decreased cell proliferation and angiogenesis in these tumours. Our findings support that THC- and CBD-loaded microparticles could be used as an alternative method of cannabinoid delivery in anticancer therapies.
too many PRs
one month target $1.00
three month target $5.00
half year target $10.00
one year target $100.00
GO GO GO!
Any one know the solid evidence of phytiva and patients information sold to XCHC by CBIS? I do not see those in 8K and 10K from both company.
Is this the website to complaint for possible securities fraud?
http://www.sec.gov/complaint/select.shtml
Can kane transfer the properties from CBIS into XCHC without any notice to public, such as 8K?
Are there any regulations/laws from SEC for this situation? If possible, any body know how to file a complaint to SEC for that?
Just curious what kane wants, money or others?
What are the views of other persons from CBIS? connive or ignore?
So XCHC management team believes they are very smart?
I just want to know which company those patients and documents belong to, CBIS or XCHC? Is the PR good for XCHC, bad for CBIS? Thanks!
those patients are all from CBIS, aren't they?
What happen?
Run Again!
GO GBEN
Xchc is over, Kane
It is time for cbis, Kane
No sell at 0.046, i need more
Go cbis
That is great for cbis!
Waiting for the stronger PRs
Go cbis
Cannabis Science in Australia
Spruce Dlask Pty Ltd
February 2011 – Present (2 years 4 months)
Spruce Dlask Pty Ltd is a recently formed Australian based company located in Melbourne with associates in the USA & Europe.
The company was created after an observation in the United States of a particular medicine plant and its subsequent success in treating cancer and related illnesses. The Companies founder Jacqueline Spruce is convinced people are ready to embrace alternative methods for treating cancer, especially after experiencing her own healing of cancer from this remarkable medicine plant. We are concentrating initially on a topical application for “skin cancer”, where Australia currently holds the title of having the highest rate per person in the world today. We will then move on to target other cancers where we have seen incredible success including prostate, breast,lung,throat and blood cancer.
Spruce Dlask is committed to a long term investment in the alternative medical industry. We aim to highlight to Australians and the world the impressive results of this medicine and ensure its recognition on the global medical scene.
Cbis will be running and over $0.20 in May based on its history
It should be released after FDA trail
Do not worry
Do not worry about it, very soon
Are you serious to talk about cbis?
If so, just tell you all you evedience is not harmful to cbis
Because cbis product is not used by smoking
Please read all documents of cbis if you are serious
Thanks
Go cbis
XCHC will be below $0.05 soon
live your dream and never wake up
hahahhaahha
GO CBIS
Great! GO CBIS
Hahhahah for those persons of another side on CBIS board!
GO CBIS!
do your dd with your brain
just because A share not issued, CBIS can raise money from that for FDA affairs
hahahha
you lose money? Ha ha ha
CBIS still has 100mil A share.
Do your dd
Ha hahahha
how do you figure out bankruptcy?
Mr. Richard C. Cowan served as the Chief Financial Officer, Principal Accounting Officer & Secretary of Cannabis Science, Inc. and served as its Treasurer since July 2009. He served as Chief Financial Officer of Gulf Onshore, Inc. since March 30, 2009 and also served as its Secretary & Treasurer. He also served as the President and Chief Executive Officer of Brazil Gold Corporation from September 2008 to January 30, 2009. Mr. Cowan served as Chief Executive Officer of the National Organization for the Reform of Marijuana Laws (NORML). He has broad knowledge of the medical cannabis world in USA, Canada, and Europe. He serves as a Director of Cannabis Science, Inc. He served as a Director of Gulf Onshore, Inc. since March 30, 2009 and Brazil Gold Corporation from September 2008 to January 30, 2009. Mr. Cowan has a Bachelor of Arts in Economics from Yale University in 1962.
Schedule 13G is an alternative SEC filing for the 13D which must be filed by anyone who acquires ownership in a public company of more than 5% of the outstanding stock. The 13G filing is considered a more passive version of the 13D and has fewer reporting requirements than the 13D. Activist practices are not permitted by 13G filers unless they refile a 13D.
You are totally wrong
1 cbis has good future
2 reverse usually happens when a stock share over billions, please do dd
3 cbis need money, but reverse does not create money
4 cbis has 100mil A share
Run and roar
Go cbis
Money wiill be back to cbis
please calm down
Why do you waste your time on cbis as you said cbis is scam?
only persons who hold cbis before, hold cbis now, will hold cbis may pay attention to cbis
Which type you belong to?
Do not tell us you are scarifying your time for others
donot mislead other people
shame on you
that is great
they need cbis
go cbis
any news from seattle?
Any news from Seattle?
GO CBIS
when stopping?
why we believe you?